Hims & Hers Health Inc. ($HIMS) is set to join the S&P SmallCap 600 index, resulting in a significant pre-market price increase of 5.3%. The stock has seen rapid growth, rising from $13 to almost $20 in about a month. Analysts predict that the stock could reach $21 in the next 1-2 days, a 10% increase. The inclusion in the S&P SmallCap 600 has driven a 22% rise in the stock last week. Despite a brief sell-off of approximately 10% due to a tirzepatide shortage, the stock recovered quickly. Hims & Hers Health has achieved $100 million in recurring revenue over two quarters with older, generic weight-loss medications. The company is expected to benefit from the potential $35 billion boost in spending on obesity drugs through 2034.